Shafique Virani - Jun 1, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Business Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jun 1, 2023
Transactions value $
-$374,034
Form type
4
Date filed
6/5/2023, 06:29 PM
Previous filing
May 17, 2023
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$215K -25K -13.38% $8.58 162K Jun 1, 2023 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$160K -17.9K -11.04% $8.93 144K Jun 2, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
F2 Includes 1,717 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023.